Explain this page
Arphra AIPlain-English read on Alnylam Pharmaceuticals, Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Peers
No peer list available for ALNY.
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.24% | +1.65% | +0.72% | -10.42% | -34.39% | -25.00% | -2.56% | +58.07% | +106.71% | +322.80% | +4862.40% |
Aftermarket
LiveLast trade
$298.87
3 sh
Bid
$298.24
26 sh
Ask
$298.51
19 sh
Spread
$0.270
Sector & industry today
LiveSectors
- Technology+3.38%
- Energy+0.94%
- Basic Materials+0.37%
- Consumer Cyclical-0.13%
- Industrials-0.31%
- Communication Services-0.37%
- Real Estate-0.60%
- Utilities-0.68%
- Healthcare-0.80%
- Financial Services-0.92%
- Consumer Defensive-0.96%
Top industries (issuer's industry highlighted)
- Biotechnology-2.16%
- Computer Hardware+6.42%
- Software - Infrastructure+5.46%
- Coal+4.85%
- Luxury Goods-4.09%
- Software - Application+4.01%
- Medical - Healthcare Information Services+3.93%
- Consulting Services+3.57%
- Semiconductors+3.46%
- Copper+3.15%
- Staffing & Employment Services+2.94%
- Integrated Freight & Logistics+2.74%
Fair value
Football field →Weighted blend
$56.66
-81.02% vs spot
Recommendation
Sell
4 of 4 methods
Method spread
0bull4bear
±5% threshold
Analyst PT consensus: $445.67 (+49.32%)
Total assets
$4.97B
Total debt
$1.28B
Cash & equiv
$1.66B
Operating CF
$524.08M
Free cash flow
$465.38M
Buybacks
$0
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Buildmarketbeat.com·May 13, 2026
- New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burdenbusinesswire.com·May 12, 2026
- New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burdenbusinesswire.com·May 12, 2026
- Alnylam to Webcast Presentations at Upcoming Investor Conferencesbusinesswire.com·May 07, 2026
- Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CMbusinesswire.com·May 04, 2026
- Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CMbusinesswire.com·May 04, 2026
- Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growthzacks.com·May 01, 2026
- Alnylam Pharmaceuticals: The RNAi Leader Continues To Grind Through A Quieter Yearseekingalpha.com·May 01, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $1.17B | $205.99M | $1.51 |
| Q4 Dec 2025 | $1.1B | $186.42M | $1.37 |
| Q3 Sep 2025 | $1.25B | $251.08M | $1.84 |
| Q2 Jun 2025 | $773.69M | -$66.28M | $-0.51 |
| Q1 Mar 2025 | $594.19M | -$57.48M | $-0.44 |
| Q4 Dec 2024 | $593.17M | -$83.76M | $-0.65 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $3.71B | $501.58M | $313.75M | $2.33 | +8.45% |
| FY 2024 | $2.25B | -$176.89M | -$278.16M | $-2.18 | -12.37% |
| FY 2023 | $1.83B | -$282.18M | -$440.24M | $-3.52 | -24.08% |
| FY 2022 | $1.04B | -$785.07M | -$1.13B | $-9.30 | -109.04% |
| FY 2021 | $844.29M | -$708.65M | -$852.82M | $-7.20 | -101.01% |